Comparing Coherent (COHR) & Bio-Rad Laboratories (BIO.B)

Coherent (NASDAQ:COHR) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Risk & Volatility

Coherent has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Valuation & Earnings

This table compares Coherent and Bio-Rad Laboratories’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherent $1.90 billion 1.41 $247.35 million $13.04 8.46
Bio-Rad Laboratories $2.16 billion 3.25 $122.24 million N/A N/A

Coherent has higher earnings, but lower revenue than Bio-Rad Laboratories.

Insider & Institutional Ownership

96.4% of Coherent shares are held by institutional investors. Comparatively, 0.1% of Bio-Rad Laboratories shares are held by institutional investors. 1.0% of Coherent shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Coherent and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coherent 13.00% 25.89% 14.37%
Bio-Rad Laboratories 55.13% 3.72% 2.67%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Coherent and Bio-Rad Laboratories, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherent 0 3 6 0 2.67
Bio-Rad Laboratories 0 0 0 0 N/A

Coherent currently has a consensus target price of $189.29, indicating a potential upside of 71.50%. Given Coherent’s higher possible upside, research analysts clearly believe Coherent is more favorable than Bio-Rad Laboratories.

Summary

Coherent beats Bio-Rad Laboratories on 7 of the 12 factors compared between the two stocks.

Coherent Company Profile

Coherent, Inc. provides lasers, laser-based technologies, and laser-based system solutions for a range of scientific, commercial, and industrial applications. It operates through two segments, OEM Laser Sources and Industrial Lasers & Systems. The company designs, manufactures, markets, and services lasers, laser tools, precision optics, and related accessories; and laser measurement and control products. Its products are used in markets, including microelectronics, materials processing, original equipment manufacturer components and instrumentation, and scientific research and government programs. The company markets its products through a direct sales force in the United States, as well as through direct sales personnel and independent representatives internationally. Coherent, Inc. was founded in 1966 and is headquartered in Santa Clara, California.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive News & Ratings for Coherent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply